William John Scheessele

CIK: 0001879378

Transaction Breakdown

Open Market Buys (P)1 (50.0%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)1 (50.0%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

HUMA

Humacyte, Inc.

Officer

Discretionary Trading P&L

Holdings

Transaction History (2 total)

HUMA
Humacyte, Inc.
Apr 14, 2025
Purchase(P)
Direct
6.5K shares at avg. $1.54$10K
HUMA
Humacyte, Inc.
Jan 21, 2025
Award(A)
Stock Options (right to buy)
Direct
283.1K shares-

		Type	Shares	Price		Ownership
Apr 14, 2025	HUMA Humacyte, Inc.	Purchase(P)	6,493	$1.54	$9,999	Direct
Jan 21, 2025	HUMA Humacyte, Inc.	Award(A) Stock Options (right to buy)	283,101	-	-	Direct

1-2 of 2 transactions

About Scheessele William John

Scheessele William John (SEC CIK 0001879378) files insider reports with the SEC as Chief Commercial Officer of Humacyte, Inc. (HUMA).

Signal8 holds 2 ownership filings by Scheessele William John, all Form 4s, filed between Jan 23, 2025 and Apr 15, 2025. Those filings report 2 transactions, from Jan 21, 2025 to Apr 14, 2025. Signal8's Form 4 history starts in Sep 2024.

The business address on Scheessele William John's filings is in DURHAM, NC.

Recent filings by Scheessele William John

Apr 14, 2025: Open-market purchase of HUMA shares (Form 4, code P).
Jan 21, 2025: Grant or award of HUMA derivative securities (Form 4, code A).

Other insiders filing for Humacyte, Inc. (HUMA)

COWARD D SCOTT, Director
Kuznik Paul Brian, Director
Jones Keith Anthony, Director
Windham-Bannister Susan Richards, Director
Constantino Michael T., Director
Wallace Max N., Director

How to read Form 4 transaction codes